

Date: 14th November, 2024

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
P.J Towers, Dalal Street,
Mumbai 400001

Script Code: 540359

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. November 14, 2024 inter alia has considered and approved:


1. The Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2024. The same has also been reviewed by the Audit Committee in its meeting held today.
2. B A Shah S R Mehta & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter and half year ended on September 30, 2024 and the Board has also taken on record their Limited Review Report on the said Results.

The Board Meeting commenced at 4:00 PM and concluded at 5:00 PM

You are requested to kindly take the above information on your record.

Thanking you.

For Parmax Pharma Limited


Bhakti Aghera
Company Secretary

Encl a/a

Statement of Standalone Unaudited Results for the Quarter & Half year ended 30.09.2024

(In Rs.
Thousands)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	92774.88	78163.00	40680.96	170937.89	54682.38	110530.35
II.	Other income	1165.23	80.14	93.34	1245.37	230.30	481.16
III.	Total Income (I+II)	93940.12	78243.14	40774.30	172183.26	54912.68	111011.50
IV.	Expenses				0.00	0.00	
	(a) Cost of materials consumed	74361.19	61739.05	13824.44	136100.24	16652.33	70292.73
	(b) Purchase of stock-in-trade	0.00	0	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-315.19	-3085.71	13525.27	-3400.90	14986.03	230.00
	(d) Employee benefits expense	8212.15	7484.86	8489.54	15697.01	15739.46	29107.93
	(e) Finance Costs	1288.50	1126.16	1812.56	2414.66	3029.70	6216.78
	(f) Depreciation and amortisation expense	4033.60	3962.24	4322.62	7995.84	8510.44	17116.70
	(g) Other expenses	8529.48	6893.34	12484.09	15422.83	21467.88	44606.10
	Total expenses (IV)	96109.73	78119.94	54458.52	174229.68	80385.84	167570.25
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-2169.61	123.20	-13684.23	-2046.42	-25473.17	-56558.74
VI.	Exceptional Items	0.00	0	0.00	0.00	0.00	0
VII.	Profit/ (Loss) before tax (V-VI)	-2169.61	123.20	-13684.23	-2046.42	-25473.17	-56558.74
VIII.	Tax expense:				0.00	0.00	
	(1) Current tax	0.00	0	0.00	0.00	0.00	
	(2) Deferred tax	0.00	0	0.00	0.00	0.00	946.47
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-2169.61	123.20	-13684.23	-2046.42	-25473.17	-57505.22
X.	Profit/(loss) from discontinued operations	0.00			0.00	0.00	
XI.	Tax expense of discontinued operations	0.00	0	0.00	0.00	0.00	0
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00		0.00	0.00	0.00	0
XIII.	Profit (Loss) for the period (IX+XII)	-2169.61	123.20	-13684.23	-2046.42	-25473.17	-57505.22
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0	0.00	0.00	0.00	0
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-2169.61	123.20	-13684.23	-2046.42	-25473.17	-57505.22
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.00	37413000
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic (In Rs)	-0.58	0.03	-3.66	-0.55	-6.81	-15.37
	(b) Diluted						

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14.11.2024
2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2024
3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 30th September, 2024 in the prescribed format under Schedule III of Companies Act, 2013
5. The figures for the previous period have been regrouped wherever necessary.

Place: Rajkot
Date: 14.11.2024


FOR, PARMAX PHARMA LIMITED
Dr. Umang Gosalia
Managing Director

STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2024		(In Rs. Thousands)	
Sr. No.	Particulars	As at 30.09.2024 (Unaudited)	As at 31.03.2024 (Audited)
I.	Assets		
1	Non-current assets	87557.96	92716.20
	(a) Property, Plant and Equipment	12494.02	1040.74
	(b) Capital work-in-progress	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Goodwill	0.00	0.00
	(e) Other Intangible assets	0.00	0.00
	(f) Intangible assets under development	0.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(h) Financial Assets	6.00	6.00
	(i) Investments	0.00	0.00
	(ii) Trade receivables	0.00	1839.34
	(iii) Loans	0.00	0.00
	(i) Deferred tax assets (net)	0.00	0.00
	(j) Other non-current assets	0.00	0.00
	Total Non-Current Assets	100057.98	95602.29
2	Current assets	27153.15	23949.37
	(a) Inventories		0.00
	(b) Financial Assets	0.00	0.00
	(i) Investments	8614.11	18159.97
	(ii) Trade receivables	815.55	510.30
	(iii) Cash and cash equivalents	0.00	
	(iv) Bank balances other than (iii) above	12664.54	15083.90
	(v) Loans	0.00	0.00
	(vi) Others (to be specified)	0.00	0.00
	(c) Current Tax Assets (Net)	2259.79	0.00
	(d) Other current assets		
	Total Current Assets	51507.14	57703.53
	Total Assets	151565.123	153305.82
II.	EQUITY AND LIABILITIES		
1	Equity	44511.50	44511.50
	(a) Equity Share capital	-45504.52	-43458.10
	(b) Other Equity	-993.02	1053.40
	Total Equity		
2	LIABILITIES		
i.	Non-current liabilities	0.00	0.00
	(a) Financial Liabilities	57519.00	59064.78
	(i) Borrowings	0.00	0.00
	(ii) Trade payables	0.00	0.00
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
	(b) Provisions	0.00	1066.65
	(c) Deferred tax liabilities (Net)	0.00	0.00
	(d) Other non-current liabilities	0.00	0.00
	Total of Non-Current Liabilities	56525.98	61184.82
ii.	Current liabilities	0.00	0.00
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	76919.36	73906.93
	(ii) Trade payables	0.00	0.00
	(iii) Other financial liabilities (other than those specified in item (c))	14217.66	15960.59
	(b) Other current liabilities	3902.13	2253.49
	(c) Provisions	0.00	0.00
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Total of Current Liabilities	95039.14	92121.00
	Total Equity and Liabilities	151565.12	153305.82

Place: Rajkot
Date: 14.11.2024

PARMAX PHARMA LIMITED

FOR, PARMAX PHARMA LIMITED

Dr. Umang Gosalia
Managing Director

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504


Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024			
			(Amt. Rs. Thousands)
PARTICULARS	Half Year Period	Half Year Period	Period Ended on
	Ended on 30/09/2024	Ended on 30/09/2023	31/03/2024
	Unaudited	Unaudited	Audited
(A) CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit After Extraordinary Item but Before Taxation:	-2046.42	-26702.15	-56558.74
Adjustments for:	7995.84	8510.44	17116.70
Depreciation	0.00	0.00	0.00
Provision for Current Tax			1290.50
Current tax expenses relating to prior year	0.00	0.00	-344.03
Provision for Deferred Tax Assets			
Operating profit before Working Capital changes	5949.42	-18191.71	-40732.55
Adjustments for changes in Working Capital:			
(Increase) / Decrease in Inventories	-3203.79	19178.56	19111.69
(Increase) / Decrease in Trade & Other Receivables	9545.86	-15989.85	-11932.52
(Increase) / Decrease in Short term Loans and Advances	159.57	10768.81	6847.96
Increase / (Decrease) in Current Liabilities	2918.14	-5103.85	28188.51
Increase / (Decrease) in Tax Provisions	0.00	0.00	-7433.63
(Increase) / Decrease in Non Current Assets	0.00	1980.70	3961.40
(Increase) / Decrease in Long term Loans & Advances	1839.34	-771.51	26.49
Cash generated from Operations	11259.12	10062.86	38769.91
Net Cash from Operating activities	17208.54	-8128.85	-1962.64
(B) CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Fixed Assets	-14290.87	-4630.09	-15868.86
Net Cash from / (Used in) Investing activities	-14290.87	-4630.09	-15868.86
(C) CASH FLOW FROM FINANCING ACTIVITIES			
Increase / (Decrease) in other Long Term Borrowings	-2612.42	10080.69	14273.87
(Increase) / Decrease in Non Current Investment	0.00	0.00	0.00
Net Cash (Used in) Financing activities	-2612.42	10080.69	14273.87
Net Increase in Cash & Cash Equivalents (A + B + C)	305.25	-2678.25	-3557.62
Cash & Cash Equivalents at the beginning of the year	510.28	4067.91	4067.91
Cash & Cash Equivalents at the end of the year	815.54	1389.65	510.28

Place: Rajkot
Date: 14.11.2024

FOR, PARMAX PHARMA LIMITED

Dr. Umang Gosalia
Managing Director



PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To
The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and Six months ended **30th September 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14th November 2024**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:

(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or

mbshah_31@hotmail.com



B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot
Date: 14.11.2024



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO: 128796W

Malay B Shah

MALAY B SHAH
Partner
M. No. 159526
UDIN : 24159526BKFOSJ8083

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:

(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or

mbshah_31@hotmail.com